StockNews.AI
CVS
StockNews.AI
188 days

CVS HEALTH CORPORATION REPORTS FOURTH QUARTER AND FULL-YEAR 2024 RESULTS

1. CVS reported a revenue increase to $97.7 billion in Q4, 4.2% growth. 2. Full-year EPS guidance is set between $4.58 and $4.83, reflecting stability.

2m saved
Insight
Article

FAQ

Why Bullish?

The growth in revenue and guidance improvement indicates solid financial health, similar to past successful quarters.

How important is it?

The revenue growth and earnings guidance could influence investor sentiment and stock price significantly.

Why Short Term?

Immediate market reactions may occur due to quarterly report results, akin to previous earnings updates.

Related Companies

CVSWBACIUNH
Fourth Quarter Highlights Total revenues increased to $97.7 billion, up 4.2% compared to prior year GAAP diluted EPS of $1.30 and Adjusted EPS of $1.19 Full-Year Highlights Total revenues increased to $372.8 billion, up 4.2% compared to prior year GAAP diluted EPS of $3.66 and Adjusted EPS of $5.42 Generated cash flow from operations of $9.1 billion 2025 Full-Year Guidance GAAP diluted EPS guidance range of $4.58 to $4.83 Adjusted EPS guidance range of $5.75 to $6.00 Cash flow from operations guidance of approximately $6.5 billion CEO Commentary "Our integrated model allows us to uniquely deliver a simpler, connected experience that saves time, saves money, and improves health. We have continued to see growth in key areas of our business, including the Pharmacy and Consumer Wellness segment, while we address the industry-wide challenges that have impacted our Health Care Benefits segment.

Related News